Active replication — ongoing trial, registry, or meta-analysis.
SGLT2 inhibitor class benefits observed in type 2 diabetes cardiovascular outcome trials will generalize to the broader HFrEF population, including patients without diabetes.
TL;DR · AI-generated
Among patients with heart failure and a reduced ejection fraction, the risk of worsening heart failure or death from cardiovascular causes was lower among those who received dapagliflozin than amongThose who received placebo, regardless of the presence or absence of diabetes.
Author-implied confidence
80%
Live consensus
Status
DRAFT
Your position — does this noeme still stand given current evidence?
0% (impossible)
50%
100% (certain)
Proper-scoring-rule preview
Your position is kept on this device until you sign in.
Evidence stream
1 event · 1 snapshot
posterior drift
91% → 91% (0pp · 1 point)
Peer-reviewed paper
Apr 18, 2026
Expert reactions · 0
Sign in to post a take, cite a related claim, or flag a methodological concern.
No reactions yet. Be the first expert to post a take, cite a related claim, or flag a methodological concern.
Source publication
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
· openalex W2974260792 · s2 43e5c9ff
Semantically related
Nearest claims in the expert-corpus vector space. Ordered by cosine distance — lower is closer.
0.0871
The cardiovascular benefit of dapagliflozin in HFrEF patients is independent of the presence or absence of type 2 diabetes, suggesting glucose-independent mechanisms of action.
0.1030
The DAPA-HF trial's stated primary conclusion — Dapagliflozin reduces heart-failure worsening and CV death in HFrEF with or without diabetes. — replicates in independent cohorts.
0.1039
The EMPEROR-Reduced trial's stated primary conclusion — Empagliflozin reduces cardiovascular death or heart-failure hospitalization in HFrEF regardless of diabetes status. — replicates in independent cohorts.
0.1485
Dapagliflozin reduces cardiovascular mortality (HR 0.82; 95% CI 0.69–0.98) in patients with HFrEF compared to placebo.
0.1490
Dapagliflozin does not increase the frequency of adverse events related to volume depletion, renal dysfunction, or hypoglycemia compared to placebo in HFrEF patients.
0.1545
Dapagliflozin 10 mg once daily reduces the composite of worsening heart failure or cardiovascular death (HR 0.74; 95% CI 0.65–0.85) compared to placebo in patients with HFrEF (EF ≤40%), regardless of diabetes status.